We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients (CACSK2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01101698
Recruitment Status : Unknown
Verified April 2010 by Medical University of Lodz.
Recruitment status was:  Recruiting
First Posted : April 12, 2010
Last Update Posted : April 13, 2010
Information provided by:
Medical University of Lodz

Brief Summary:

Vessel calcification is a recognised cardiovascular morbidity risk factor in patients with chronic kidney disease (CKD). Recent reports indicate a significant role of Matrix Gla-protein (MGP) in decreasing calcification processes. MGP is excretion protein whose mechanism of action is not yet fully explained and which to be activated requires phosphorylation and carboxylation where cofactor is vitamin K. These observations indicate that shortage of vitamin K is a significant risk factor for the development of vessel calcification. Another calcification risk factor in CKD patients are calcium-phosphate disturbances and insufficiency of vitamin D3 which in physiological concentration stimulates MGP transcription. The aim of this study is estimation of influence of vitamin K2 administration over the period of 9 months on vessel calcification in 3.- 5. stage CKD patients.

It is a prospective, randomised double-blind study carried out in parallel groups. 60 patients with CKD (GFR 15-60 ml/min) with calcium score >10 (Agatston scoring system) will be qualified for the study. On the basis of randomised selection, patients will be divided into two groups: 30 patients will be given 90 μg vitamin K2 + 10 μg and cholecalciferol 30 patients will be given only 10 μg cholecalciferol. After a 9-month treatment the image diagnostic will be carried out in order to estimate the degree of vessel calcification.

Condition or disease Intervention/treatment Phase
Kidney Diseases Coronary Artery Calcification Drug: Vitamin K2+10μg cholecalciferol Drug: Vitamin D Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease
Study Start Date : June 2009
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : June 2011

Arm Intervention/treatment
Active Comparator: Vitamin K2, calcification score changes, vitamin D
90 μg vitamin K2+10μg cholecalciferol
Drug: Vitamin K2+10μg cholecalciferol
Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months

Drug: Vitamin D
Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months

Active Comparator: Vitamin D, calcium score changes
10μg cholecalciferol (vitamin D)
Drug: Vitamin K2+10μg cholecalciferol
Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months

Primary Outcome Measures :
  1. Changes in coronary artery calcification score [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Changes in common carotid artery intima media thickness [ Time Frame: 9 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject with chronic kidney disease (creatinine clearance 15-60 ml/min/1,73m2 by Cockroft-Gault formula)
  2. Patient has a life without dialysis therapy of more than 9 months
  3. Subject in 30-70 years of age
  4. Calcium score >10 (as per Agatston scoring system)

Exclusion Criteria:

  1. Atherosclerosis generalisata (myocardial infarction treated with PTCA - Percutaneous Transluminal Coronary Angioplasty or CABG - Coronary Artery Bypass Graft, symptomatic heart insufficiency, cerebrovascular accident)
  2. Subject with a history of cardiac abnormalities, including symptomatic or asymptomatic arrhythmias (atrial fibrillation)
  3. Patient with cardiac pacemaker
  4. Subject requires long-term use of vitamin K antagonists

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01101698

Layout table for location information
Department of Nephrology, Hypertension and Kidney Transplantation Recruiting
Łódź, Poland, 90-153
Contact: Michał Nowicki, Prof    0048426776709    nefro@wp.pl   
Contact: Ilona Kurnatowska, MD    0048509293095    ilona.kurnatowska@umed.lodz.pl   
Principal Investigator: Michał Nowicki, Prof         
Sponsors and Collaborators
Medical University of Lodz
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Prof Michał Nowicki, Department of Nephrology, Hypertensiology and Kidney Transplantation Medical University of Łódź
ClinicalTrials.gov Identifier: NCT01101698    
Other Study ID Numbers: CACSK2
First Posted: April 12, 2010    Key Record Dates
Last Update Posted: April 13, 2010
Last Verified: April 2010
Keywords provided by Medical University of Lodz:
Vitamin K
chronic kidney disease
coronary artery calcification
intima media thickness
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Calcium Metabolism Disorders
Metabolic Diseases
Vitamin D
Vitamin K
Vitamin K 2
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action